3 Reasons Caribou Biosciences Could Be the Best Gene-Editing Stock for Your Portfolio

·5-min read
3 Reasons Caribou Biosciences Could Be the Best Gene-Editing Stock for Your Portfolio
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Caribou Biosciences (NASDAQ: CRBU) filed its paperwork for an initial public offering (IPO) only days after Intellia's announcement. The company was co-founded by Jennifer Doudna, who shared the 2020 Nobel Prize in Chemistry for her discovery of the CRISPR-Cas9 gene-editing tool. Although she is not employed by the company, she still serves on its scientific advisory board.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting